You are here: Industry Insights > Vascepa

News List

Drug approved which reduces risk of cardiovascular events europeanpharmaceuticalreview
December 18, 2019
The FDA has approved Vascepa (icosapent ethyl) as a secondary therapy to reduce cardiovascular events in adults.
Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in fiercepharma
May 09, 2019
Amarin spent years, millions of dollars and a lot of willpower proving its fish oil-based drug Vascepa really could cut the risk of heart attacks, strokes and other cardiovascular problems. To make that effort pay off, it needs to keep that proof to itsel
Amarin’s Vascepa nabs ADA backing to cut heart risks, even ahead of FDA review fiercepharma
April 02, 2019
The cardiovascular outcomes results Amarin rolled out for its fish oil-derived Vascepa may not have impressed all……
Amarin rolls out more Vascepa heart benefits data to back label expansion fiercepharma
March 19, 2019
Amarin has rolled out new Vascepa data that could change the way doctors prevent heart disease. Monday, the company trumpeted more data showing its fish oil-derived Vascepa could significantly cut heart risks, and the drugmaker plans to add the benefits t
Why Amarin's Latest News Caused Shares to Crash 13% Today fool
November 28, 2018
After the company announced a $200 million secondary offering of its American Depository Shares (ADS), Amarin Corporation plc (NASDAQ:AMRN) shares tumbled 13% on Tuesday......
Amarin’s Vascepa cuts heart risks in key trial, but placebo noise fuels controversy fiercepharma
November 15, 2018
Some expecting a home-run win from Amarin’s heart drug Vascepa in cardiovascular benefits might leave the American Heart Association annual meeting feeling less excited.
Amarin says detailed REDUCE-IT results bolster CV risk reduction claims for Vascepa, but some question whether placebo used may have exaggerated benefit pharmafile
November 12, 2018
Detailed data from the REDUCE-IT cardiovascular (CV) outcomes study of Amarin's Vascepa (icosapent ethyl) presented at the American Heart Association (AHA) meeting
Believe it: Just as Amarin promised, Vascepa delivers big win in heart-risk study fiercepharma
September 30, 2018
WIth standard statin therapy covered by cheap generics, newer branded drugs have looked to outcomes studies to show they can reduce heart risks.